Effect of using fidaxomicin on recurrent Clostridium difficile infection

Martin Biggs, Tariq Iqbal, Elisabeth Holden, Victoria Clewer, Mark I. Garvey

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)
172 Downloads (Pure)


Fidaxomicin is a macrocyclic antibiotic licensed for treating Clostridium difficile infection (CDI). In the UK, fidaxomicin is often reserved for severe CDI or recurrences. At Queen Elizabeth Hospital Birmingham, all courses of fidaxomicin during 2017/2018 were reviewed. Thirty-eight patients received fidaxomicin, of which 64% responded to treatment when fidaxomicin was given during the first episode of mild CDI. Conversely, all patients with recurrent CDI failed treatment with fidaxomicin. There were mixed results for the use of fidaxomicin for severe CDI, with only 42% of patients responding. These results suggest that fidaxomicin is best suited as a treatment for mild CDI during a patient's first episode.

Original languageEnglish
Pages (from-to)165-167
Number of pages3
JournalThe Journal of hospital infection
Issue number2
Early online date4 Jan 2019
Publication statusPublished - Jun 2019


  • clostridium difficile
  • recurrence
  • fidaxomicin


Dive into the research topics of 'Effect of using fidaxomicin on recurrent Clostridium difficile infection'. Together they form a unique fingerprint.

Cite this